ABSTRACT

The cytotoxic T lymphocyte (CTL, Tc) is a type of T lymphocyte/white blood cell involved in the host’s cell-mediated immune response against cancerous cells, abnormal cells and cells infected with viruses. Signals from infected cells or cancer cells lead to the release of cytotoxins: perforin, granzymes, and granulysin by the Tc cells. The activation of CTLs is mediated by the interaction of various co-stimulatory molecules as well as immune cells. Pre-eminent role of CTLs in combating cancer can be effectively applied for the active and passive immunotherapeutic approaches. Various recombinant cytokines viz., interleukins (IL)-2, 4, 7, 10, 12, 15; tumor necrosis factor (TNF) have been found to augment the production of CTL. CTLs can also be stimulated in antigen specific manner through tumor antigens which are the molecular derivatives over expressed in tumor cells due to differentiation, point mutations or viral origin. Designing and development of vaccines based on such immunogenic candidates can be executed and in majority of cases such antigens are targets for CTLs. Identification as chemotherapy and CTL-mediated killing, and validation of these CTL-specific antigens require...
I Introduction

In the later part of the 19th century one of the lengthiest goal in developing immunotherapy against cancer has been achieved. In this quest developments in the recent years have rejuvenated the optimistic sense. Few of the malignant cancers can now be treated by employing monoclonal antibodies (MAbs) which are highly specific and can provide accurate diagnosis. Apart from conventional anti-cancer therapeutics available, some of the upcoming therapeutic regimens include cytokines (Dhama et al., 2013a), tumor homing peptides (Khandia et al., 2016a), heat shock proteins (Khandia et al., 2016b), zootoxins (Mohanty et al., 2016), bacterial toxins (Khandia et al., 2017a), cell penetrating peptides (Khandia et al., 2017b), nanotechnology-based drugs (Iqbal et al., 2016; Ahmad et al., 2017), biomarkers guided therapy (Dadar et al., 2016); immunotherapy and molecular approaches (Dhama et al., 2014; Acharya et al., 2015; Dhama et al., 2015); apoptosis (Kumar et al., 2015); herbs and plant metabolites like Guduchi, Noni, green tea etc. (Dhama et al., 2013b; Saminathan et al., 2013; Dhama et al., 2016), panchgavya elements (Dhama et al., 2013c) and others. These are crucial advances of course but it is suggestive on the basis of much more evidences that harnessing of the cellular immune system may prove more efficacious to the endeavour (Maher & Davies, 2004; Abbas et al., 2007; Zou & Restifo, 2010). Cytotoxic T lymphocyte (CTL) is the other name of cytotoxic T cell; also known as T-killer cell; cytolytic T cell; CD8+ T-cells or killer T cell; Tc. Such type of T lymphocyte/white blood cell helps to destroy cancer cells particularly the ones that are virus-infected. A specific antigen which is produced by cancer cells or virus-affected cells is recognized by most cytotoxic T cells which express T-cell receptors (TCR). The class I Major Histocompatibility Complex (MHC) bind antigens inside a cell and bring them to the cell surface where their recognition is done by T cells. For the binding of TCR to the complex of the class I MHC molecule, a glycoprotein known as cluster of differentiation (CD) 8 must accompany the former so that it can bind to the constant portion of the class I MHC molecule. Thus, such T cells are known as CD8+ T cells. The binding of Tc and the target cell is helped by the affinity between CD8 and the MHC molecule during the antigen-specific activation. Once activated, there is recognition of the CD8+ T cells as Tc cells. Cytotoxic role is therefore performed by them within the immune system. Even though the CTLs are tiny (measures about a tenth of the human hair width) they certainly form crucial line of defence against infections as well as tumours (Wilke et al., 2011; Hivroz et al., 2012; Dhama et al., 2013a; Hoyer et al., 2014).

It is a fact that CTLs mediate defence against abnormal or infected cells but cannot recognize free/have antigens in circulation. Cellular defence of CTLs is induced by the recognition of endogenously processed antigens expressed on the surface of infected/cancerous cells along with MHC I molecules. CTL antigen binding is therefore always restricted to the MHC determinants correctly. The CTLs thereafter proliferate as well as differentiate. There is promotion of this event by a variety of cytokines viz., interleukin (IL)-1; IL-2; as well as IL-112. There is unique alteration morphologically in association with the activation of CTL (antigen-specific). There is therefore increase in cell size; they become polarized, highly forming lysosomal granules uniquely that contain a pattern of lytic proteins specifically. A sequence of predetermined steps is followed by the target cell lysis via CTL. This include: binding of killer-target cell; delivery of lethal hit; target cell lysis; and killer cell recycling. Following the recognition of appropriate antigen, CTL firmly binds to the target cell surface on the basis of presence of Mg2+ (but not Ca2+). Subsequently two different mechanisms mediate target cell lysis; exocytosis of lytic proteins; and/ or binding of receptor-ligand (of Fas molecules) (Groscurth & Filgueira, 1998; Freiberg et al., 2002; Taniguchi et al., 2003; Jahang et al., 2004; Gabrilovich & Nagaraj, 2009). This review focuses on how cytotoxic T lymphocytes (CTLs) may be used as target for immunotherapy against cancer; especially lung cancer and certain virus-induced cancers.

2 Effector functions of Tc cells

On exposure to infected/ dysfunctional somatic cells there is release of cytokotins viz., perforin, granzymes, and granulysin by the Tc cells. Granzymes enter the cytoplasm of the target cell via the action of perforin. The serine protease functions to trigger the caspase cascade, which is a chain of serine proteases eventually leading to apoptosis. Otherwise it is referred to as programmed cell death. Interaction between the Tc and the infected cells is a second mode of induction of apoptosis. The Tc upon activation...
expresses FAS ligand (surface protein)/ FasL (Apo1L) (CD95L) (binding to Fas (Apo1) (CD95) molecules and target cell expressing them). However the interaction between Fas-Fas ligand is crucial as far as the disposal of unwanted T lymphocytes or lytic activity of certain T_H cells are concerned. The death-induced signalling complex (DISC) is recruited when Fas is engaged with FasL. Pro caspases 8 as well as 10 are recruited due to translocation of the Fas-associated death domain (FADD) with the DISC. This is followed by activation of effector caspases 3, 6 and 7. This causes cleavage of death substrates like lamin A; lamin B1; lamin B2; poly ADP ribose polymerase (PARP); and DNA-activated protein kinase (DNAPK). This leads to the final result which is nothing but the cellular apoptosis on the basis of expression of Fas (Matteo et al., 2005; Subramanian & Ramalingam, 2005; Matteo et al., 2006; Gabrilovich & Nagaraj, 2009; Milstein et al., 2011; Lui-Roberts et al., 2012). The mechanism of tumor cell killing by CTLs has been illustrated in Figure 1.

---

Figure 1 CTL mediated cancer cell killing (1) Tumor specific proteins are expressed in cancer cells (2) Tumor peptides are processed and presented over the surface of cell by HLA molecules (3) HLA presented peptide is recognized and bound by CTL (4) Binding initiates cascade of reactions for expressing FAS ligand (FASL) to (5) Engage FAS receptors present on the tumor cell (6) Leading to initiation of activation of procaspase 8 and 10 (7) and result in subsequent apoptosis (8) CTL produces perforin and granzymes (9) Perforin are polymerized to form pore into cancer cells and (10) Granzymes enters the cancer cells through the pore formed by perforins and (11) cleaves functional proteins and DNA to cause apoptosis.
potent immunological functions CTLs can be employed in case of malignancies of various origin due to expression of MHC class I molecules in wide spread fashion. These are over the time recirculated for seeking out antigen; a single peptide-MHC class I complex can elicit effector CTL mediated cytolysis pathway with high avidity for target recognition (Sykulev et al., 1996; Hanlon et al., 2002; Qiu et al., 2003).

Effectors CTLs are regulated by depending on the naive CD8+ T cells (antigen-driven in nature) differentiation, and when dendritic cells (DC) get in contact with antigen. This results in migration to the regional lymph nodes. Here with naive T lymphocytes there is interaction of the DCs. The result is recirculation through secondary lymphoid tissue. The DCs must be in activated state for achieving optimum CTL priming and is achieved when there is presentation of processed antigen to MHC class II-restricted CD4+ helper T cells. Then there is subsequent upregulation of CD40 ligand thereby causing engagement of DC-associated CD40 (Lanzavecchia, 1998; Hayakawa et al., 2001; Fuji et al., 2004; Kumar et al., 2015).

CTLs interact with cognate target cells with a dual activation threshold, resulting in the formation of two distinct synapses; the lytic synapse at CTL-target cell contact site for cytotoxicity and the stimulatory synapse for activating cytokine production (Faroudi et al., 2003). The effector responses from CTLs over each target cell are executed effectively by rapid lethal hit and subsequent cycling of action on other target cells (Isaaz et al., 1995). Some cellular studies point out the CTLs exhibiting simultaneous killing of multiple target cells also, but yet to be validated in vivo (Friedl et al., 2005). This blending of serial and multiple target cell destruction facilitates effective immune surveillance and thus CTLs embodies the diversity and complexity in its effector mechanisms in the course of immune responses in eliminating abnormal cell/infected cells in pathological tissues (Wiedemann et al., 2006). CTLs are provided with strong antigenic stimuli through sustained synapses with target cells, thereby polarizing the lytic granules towards different cells and along with spatiotemporal uncoupling of immunological synapses enables the multiple killing (Callan et al., 1998; Alegre et al., 2001; Hayakawa et al., 2001; Vinay et al., 2004; Wiedemann et al., 2006).

CD4 T cells render crucial assistance in promoting cytotoxicity and survival of effector CD8 T cells especially in chronic infections and in establishing memory cells following primary response (Rajasagi et al., 2009; Phares et al., 2012). They also facilitate the entry of primed CTLs from regional lymphoid tissues into sites of infection/ abnormality (Smith et al., 2004; Nakanishi et al., 2009) and these assistance in terms of CD4 T cells are unrelated to Th effector phenotypes i.e., both Th1 and Th2 cells can mediate these functions (Ekkens et al., 2007).

CD8+ T memory cells are clinically important as they function directly in situ as cancer killer cells. The current knowledge however is suggestive of the fact that CD8+ T cells seem to be more simplified functionally in comparison to the CD4+ T cells. The reason behind is that for a stronger consensus clinically there is only one outcome due to the presence of a simple killer at the site of tumour. A high concentration of suppressor CD8+ T cells has also been noticed in patients suffering from cancers. Detection of such cells at the site of tumor can thereby reveal another layer of complexity (Andersen et al., 2009; McNally et al., 2011; Azimi et al., 2012; Kumar et al., 2015).

3 Immune tolerance and cancer

For counter action of the attention of CTL as well as other effector arms of the immune system various immune evasion strategies are adopted by cancer cells, many of which rely upon the capability of cancer cells to harness systems maintaining immune tolerance to self. Immune tolerance could happen by removing the auto reactive lymphocytes via an immunotherapeutic strategy. For therapeutic manipulation, in contrast non-deletional tolerance mechanisms work better. For instance, it has been implicated through more evidences that immune tolerance is maintained by various regulatory T cell sub sets that may include classical Treg cells (CD4+CD25+) and other associated T cells like Tr1 cells (produces IL-10); Th3 cells (produces transforming growth factor (TGF)-β); and CD8+ regulatory T-cell subsets. These immune-suppressive cells can induce tolerance towards both self and derived malignancies (Jonuleit et al., 2001; Stinchcombe & Griffiths, 2001; Nelson, 2004; Pasero et al., 2016; D’Errico et al., 2017). However, by deleting or suppressing these cellular populations, immunotherapy of malignant diseases could be strengthened (Maher & Davies, 2004). It is exciting to notice that checkpoint blockades are utilized nowadays for blocking signals that are negative thereby maintaining the response to tumours. Molecules on the surface of T cells like cytotoxic T lymphocyte antigen 4 (CTLA-4) play significant role in regulation of check point (Grosso & Jure-Kunkel, 2013; Makkouk & Weiner, 2015).

4 Role of Natural killer T (NKT) cells in induction and activation of CTLs

It has been reported in various studies that type I NKT cells’ activation is found in intimate association with the cancer cell elimination. These are lymphocytes which are unique by the expression of a single invariant antigen receptor that recognizes glycolipids associated with CD1d molecule. Since they can mediate immunopotentiating activity towards CTLs as well as NK cells, leading to the extermination of tumours without relapse, NKT cells can be very well employed in anti-tumorcellular therapy (Brigl & Brenner, 2004; Fujii et al., 2006; Lippitz, 2013; Taniguchi et al., 2015). Induction of NKT cell-targeted anti-
tumortherapy can be mediated by either IL-12 or –GalCer but difference in the stimulatory substances can lead to various patterns of cytokines production. When IL-12 is administered it can lead to production of high amount of Th-1 cytokine (or interferon’s) in type I NKT cells dependent manner/ fashion; whereas both Th-1 (Interferon’s) and Th2 (IL-4) cytokines are secreted on activation by –GalCer (Takahashi et al., 2000; Metelista et al., 2001; Prlic et al., 2003; Ambrosino et al., 2007; Kumar et al., 2015; Shanker et al., 2017). In the induction as well as activation of CTLs various cytokines; co-stimulatory molecules as well as immune cells play crucial role. Various recombinant cytokines viz., IL-2, 4, 7, 10, 12, 15; tumornecrosis factor (TNF) have been found to augment the production of CTL. The degree of enhancement depends on the specific antigen; population of cells that are responding; and several environments. Particularly IL-2 has got the potential to cause induction of particular cytotoxicity (Ludewig et al., 1999; Ulrich et al., 2005; Ito & Seishima, 2010; Dhama et al., 2013a).

5 Vaccination strategies targeting CTL to tumourantigens

For developing vaccine against cancer, one traditional approach involves the use of whole tumorcells (inactivated). There has been more recent extension of this approach along with the development of vaccines based on tumorcells which have been engineered for expression of immunomodulatory cytokines as well as co-stimulatory ligands; like that follows genetic modification or fusion with DCs (Freigang et al., 2005).

Non-viral malignancies have also been reported to express tumourantigens. On the basis of defined molecular targets there have been developments in vaccines and in majority of cases such antigens are targets for CTLs. They are derived from molecules which are over expressed in tumorcells in comparison to their normal counterparts (Van der Bruggen et al., 2002). One of the key obstacles to the breaking of the immune tolerance to cancer is recognizing close relationship between tumourantigens and ‘self’; a wide variety of vaccines (antigen-specific) are under development on the basis of peptides; protein; mRNA or DNA that are expressed from plasmid or viral vectors (Whelan et al., 2003; D’Errico et al., 2017). A panel of adjuvants promoting DC activation to enhance immunity has been reported (Cerundolo et al., 2004). Several tumorvaccines show expanded CTL responses for useful applications (Coulie & van der Bruggen, 2003; Morris et al., 2003).

Various clinical studies on the therapeutic vaccination have been performed recently on small scale basis in recent years. The safety of the approach has been confirmed by these trials in general. CTL stimulation and antibody responses have been well documented against vaccine components (Knutson et al., 2001). This is suggestive of the fact that tumours expressing defined antigens can be immunotherapeutically targeted (Finn, 2003; Morris et al., 2003).

Characterization of tumour-associated antigens has paved way for newer avenues in cancer therapy, recognized by cellular and humoral immune effectors. As targets for CTLs in vitro as well as in vivo there have been description of various types of cancer-associated antigens viz., cancer-testis (CT) antigen; melanocyte differentiation antigen and viral antigens; apart from those arise from point mutations or over expression of critical genes in malignant tissues. Several antigen-derived peptides based on these tumors associated antigens have been revealed to induce specific CTL responses through various in vivo clinical studies. Immunological and clinical parameters are available for assessing peptide-specific reactions (like induction of delayed type of hypersensitivity; autoimmune as well as tumour- regression responses). Tumour-associated antigens also cause elicitation of CTL-responses that lead to regression of tumourfollowing injection intradermally. There is tumourregression brought about by CTLs induced through peptide immunization.

Active immunotherapy with tumour-associated antigens is a promising approach to cancer immunotherapy. As a result, patients have residual disease to the minimal level. There has been human leukocytic antigen (HLA)-A2 restricted CTL reactivity in melanoma patient with antibody having higher titer against cancer-testis antigen (Jaquer et al., 1999; Johnson et al., 2002; Terabe et al., 2000; Terabe et al., 2005). Tumorvaccination in case of advanced stages of tumorproves to be relatively ineffective; but in patients with sub-advanced malignancies suitable vaccines can be of much effectiveness (with minimal residual disease). Tumor vaccination can be employed in association with other therapeutic modalities as proven to be effective in case of promyelocytic leukaemia (Padua et al., 2003; Le et al., 2010). Also, multivalent vaccines against tumors may be a viable approach as they prime CTLs to target multiple epitopes (Graff-Dubois et al., 2002). CTL responses (antigen-specific) require monitoring that can be done by various new techniques including enzyme-linked immunospot (ELISPOT); tetramer analysis and detection of cytokine intracellularly (Kurzrock, 2000; Clay et al., 2001). For antigen delivery materials-based strategies involving use of nanoparticles (polymeric); virus-like particles; liposomes; peptidomimetics etc have been adopted for enhancing immunity based on CD8+ T cells (Chesson et al., 2017).

6 Adoptive CTL therapy

There is a wide range of suitable CTLs that target several tumours at present. The first clinical tests of adoptive transfer of CTLs have been permitted by improvement in CTL cell culture technology. This approach produces an immune response which is productive and vividly studied in patients suffering from
melanoma (Perica et al., 2015). Patients suffering from refractory; metastatic melanoma can be treated in this way using CTLs that are infused following ex-vivo potentiation. These are (MART-1) CD8+ T cells which recognise melanoma antigen efficiently destroy normal melanocytes as well as tumours that are MART-1 negative. This demonstrates a tumorvariant selection with the loss of expression of MART-1. In an independent trial, such results are confirmed in such a manner that there is CTL engraftments. This is subsequently measured by a high rise in the level of T cells that are circulating and are able to bind tetramers that are fully loaded with MART-1 peptides. But the anti-tumorresponse rate is very low in patients even though the level of engraftment in patients is high. Even though CTL transfer facilitates a potent means to combat tumorgrowth, some adverse conditions still pertain and most prevalent among them is the emergence of antigenic variants. This is more reflected in human cases of tumours than with mouse syngeneic tumormodels (Norell et al., 2006).

Clinical trials based on CTL transfer in melanoma patients revealed its vaccine-like action resulting in epitope spreading. This suggesting the possibility of addressing antigenic variation and immune evasion of tumourcells through the enhancement of immune response by infusing CTLs possessing multiple antigenic specificity or by increasing efficiency to spread epitope (Marincola et al., 2000; Yee et al., 2000; Yee et al., 2002; Mackensen et al., 2006; Norell et al., 2006; June, 2007; Dhama et al., 2013a; Maude et al., 2014; Rahal et al., 2014). Improvement in adoptive cell therapy towards refractory melanoma has been developed with autologous tumourinfiltrating lymphocytes (TIL) from patients and applied in combination with recombinant interleukin-2 and non-myeloablative lympho-depleting chemotherapy (NMA). NMA conditioning of patients which is to be done before infusing the potentiated T cells, diminishes the endogenous regulatory T cells and other interfering cells, thereby enabling the survival of transferred cells (Rosenberg et al., 2011; Besser et al., 2013). It follows the demonstration of the fact that IL-2 can help to achieve responses in a small number of patients. The response rate is moderately improved upon infusion of TIL. Over period of time TIL are found to be enriched for CTLs that are MHC class-I restricted. They are specific for melanoma that are known and include: MART-1 as well as gp 100. Impressive expansion of TIL. (IL-2 driven) in vivo has been observed that causes significant increase in the clinical response rate (Rosenberg et al., 1994; Dudley et al., 2002).

7 Genetic approaches to adoptive CTL therapy

Advances in gene manipulation and cell culturing techniques deliver robust means for redirecting the specificity of T cells so that CTLs with high receptor specificity and potent cytoxicity against tumourcells can be generated for immunotherapy (Norell et al., 2006). Some prominent genetically modified anti-cancer T cells are those with chimeric antigen receptors (CARs) or neoantigen-specific T-cell receptors that are extensively used in adoptive immunotherapy as promising candidates in combating tumourcell immune evasion (Morris & Stauss, 2016; Ye et al., 2017). Development of various investigative avenues for the expansion and increase in the specificity of adoptively transferred T cells is still under process. One among them is the application of antigen-presenting cells (artificial) permitting CTL (tumour-specific) expansion in vitro and has come up with promising results. In order to achieve this, NIH3T3 fibroblasts have been genetically engineered, permitting the expression of peptide epitopes in the way similar to that of endogenous peptide i.e., in association with an MHC class I molecule and a β2 microglobulin along with series of co-stimulatory ligands. IL-15 as growth promoter has been recognized by various researchers in order to boost in vitro expansion of CTLs.

Chimeric antigen receptors are genetically engineered receptors on the surface of CTLs wherein an antibody derived single chain fragment (scFv) is coupled with intracellular signalling element via a hinge region (Maude et al., 2014). On the surface of T cells usually CARs are expressed as homodimer (coded by a single gene) enabling recognition of tumour-associated antigen in MHC-dependent manner (Kirkwood et al., 2008). There have been constructions of various fusion receptors of such kind. These have been constructed with molecular specificity expressed by malignancies that are solid as well as haematological in nature (Latouche & Sadelain, 2000; Brentjens et al., 2003; Maher & Davies, 2004; Kirkwood et al., 2008).

Since T-cell co-stimulation is not provided by most tumours, the subsequent area of interest has become the CAR development that can provide such type of accessory signals. Initial developments focused on the construction of fusion receptors of scFv (or CD28) and recently designed CAR with the fusion of signalling domains of CD3ζ and CD28. Repeated activation of such cells is facilitated by co-culturing with tumourcells (expressing antigens in vitro) and tumortargets die rapidly with each cycle of stimulation. This is followed by proliferation of CAR-grafted CTLs that are IL-2 driven. For the CAR-grafted CTLs to survive over a sustained period of time an approach is specific gene transfer into T cells responsive to Epstein-Barr Virus (EBV). They are known to persist for a prolonged period of time in vivo and thereby facilitating a sustained control of a tumorburden in vivo and provide momentum to CAR technology (Haynes et al., 2002; Maher et al., 2002; Rossig et al., 2002; Finney et al., 2004). The clinical responses against blood cancers by the use of CAR T cells are quiet noteworthy (Kershaw et al., 2014). Work is in progress to develop CARs delivering two or more co-stimulatory molecules. An alternate system to redirect the specificity of both
CD4+ and CD8+ T cells is developed by associating a defined TCR (tumorassociated) that is specific for a new MHC-peptide complex and has been tested with success in several in vitro studies (Maher, 2012; Sharpe & Mount, 2015). Permission has been granted to a greater repertoire of attractive protein antigens compared to CAR and evidences suggest that in comparison to ectopic TCR the immunogenicity of CAR derived from rodent hybridoma based scFv is found to be greater. Such advantages are however balanced by certain disadvantage like: there is requirement of co-expression of two gene products in a regulated fashion i.e. α and β chains of TCR (as the TCR is a heterodimer). In principle TCR sub units (that are endogenous in nature) may form heterodimer with such exogenous receptor subunits. This can lead to generation of complexes with potential of auto reaction. It is possible to overcome this potential difficulty by including sequences permitting only dimerisation of the ectopic TCR sub units (Gilboa, 1999; Eberl et al., 2000; Fujii et al., 2003; Hermans et al., 2003).

The microenvironment inside the tumor growth is critical with regard to the outcome of immunotherapy as it is often poorly conducive to the function of CTLs. There can be overproduction of immunosuppressive cytokines viz., TGF-β (in case of several malignancies), which can however be circumvented by genetic approaches. Suitable immunopotentiating agents like LIGHT (belongs to the tumor necrosis factor superfamily) can be genetically employed for manipulating the microenvironment alternatively. This is the reason why there are reports of recruitment of naive CTL dramatically. They get primed there eliciting anti-tumorimmunity which is impressive in nature (Gorelik & Flavell, 2001; Yu et al., 2004).

8 Role of cytotoxic T-cells in various types of cancers

8.1 Lung cancer

There is increased efficacy of treatment of both small cell lung cancer or non-small cell lung cancer (NSCLC) with the activation of the immune system. Clinical efficacy of immunomodulatory antibodies directed against cytotoxic T cell-associated antigen 4 (CTLA-4/CD152) and programmed cell death ligand 1 (PDL1/CD274) is evident too. CTLs are the main immune cells having anti-tumoractivities. The pre-requisite for the immune system to attack the cancer cells is the availability of these tumor-directed CTLs both in numbers and functionality. Lung cancer suppressive capability is known to be possessed by two types of immune cells (playing a pivotal role in patients) viz., regulatory T-cells and suppressor cells (myeloid-derived) (Matsui et al., 1999; Ikeda et al., 2004; Aerts & Hegmans, 2013). At the same time the greater rate of survival in case of NSCLC is in close association with effector T cell (CD3+CD8+) infiltration (Aerts et al., 2014).

8.2 Lymphoproliferative diseases caused by Epstein-Barr virus (EBV)

Much interest to utilize cytotoxic T cells as adoptive immunotherapy for viral as well as malignant diseases has been stimulated by an increase in the understanding of the mechanisms by which there is recognition of T lymphocytes that recognize virus as well as tumour-specific antigens. A mild as well as self-limiting illness caused by EBV in immunocompetent hosts. This is followed by a latency (life long period) wherein cytotoxic T cells (that are EBV-specific) control the viral activity in the B cells. There is involvement of EBVs in case of malignancies viz., Hodgkin’s disease as well as nasopharyngeal carcinoma (NPC). There is development of lymphoproliferation that remains unchecked in hosts with impairment of immunity to T-cell thereby leading to immunoblastic lymphoma (Curiel, 2007). In patients receiving bone marrow from family members who are mismatched or unrelated donors the frequency of such complications are highest. This happens if there is lack of T cells in the marrow to prevent graft-versus-host disease. In the unsolicited lymphocyte population EBV-specific T cells are contained from the blood of the donor peripherally. They can be utilized to control lymphoproliferative disease (caused by EBV). Complications may arise due to the presence of alloreactive T cells in the lymphocyte infusion. This in turn restricts the utilization of such therapy. Generation of EBV-specific cytotoxic T cell lines have been done from donor lymphocytes for the purpose of overcoming this obstacle. They can be used against lymphoma induced by EBV prophylactically. The infused CTLs are marked genetically to reliably monitor the cells for both their persistence and localization within the body. It has been found that such CTLs that are gene-modified can persist for an extensive period of time in vivo for retaining anti-EBV activity (Beatty et al., 1997; Rooney et al., 1998; Sakaguchi, 2000; Shankaran et al., 2001; Curiel, 2007).

9 Post transplant lymphoproliferative disease (PTLD) and nasopharyngeal carcinoma (NPC)

PTLD is characterized by the proliferation of B lymphocytes in an immuno-compromised patient. After undergoing organ transplantation, patients used to medicate with immunosuppressive drugs to prevent an impending organ rejection. This results in an uncontrolled proliferation of lymphoid cells (Dharnidharka et al., 2016). Epstein-Barr virus (EBV), a member of the herpes virus family, has been found to be involved in PTLD as a consequence of life long persistence of EBV following its primary infection (Dharnidharka & Araya, 2009). Since Cytotoxic T lymphocytes (CTLs) can control PTLD, the adoptive immunotherapy using autologous EBV-immortalized lymphoblastoid cell lines (LCLs) has been employed for more than ten years, thereby stimulating CTL expansion in an EBV-
specific manner (Abbas et al., 2007). The success of PTLD treatment has encouraged in conducting various studies to know the CTLs (activated EBV-specific) causing regression of advanced NPC. It has been thereby found that there is certainly clinical benefit of such treatment especially in patients with locoregional disease (Sherritt et al., 2003; Straathof et al., 2005). It is interesting to note that there has been demonstration of the fact that peptide vaccination may prove efficacious as has been understood by conduction of clinical trials in human. Based on this, patients with NPC are being treated using EBV-specific CTLs for assessing the potential use of adoptive transfer of CTLs (peptide activated). It has been found that in this particular disease expression of EBV gene is limited to latent membrane protein (LMP) Following adoptive transfer the infused cells containing LMP2 specific CTLs are well tolerated. Basically, the infused CTLs are not apparently found to be effective in curtailing the growth of primary tumormass in patients. Moreover, when the plasma samples of the patients have been collected a peak in the EBV DNA have been observed which is the proof of the fact that the NPC cells have undergone lysis by the action of these infused CTLs. It is also interesting to note that there is possibility that the CTLs have better access to lungs when infused (Abbas et al., 2007; Kenter et al., 2008; Kenter et al., 2009; Lutzky et al., 2014).

9.1 Human papilloma virus (HPV)-induced cervical cancer

It has been found that IL-10 combined with IL-2 can cause consistent increase in cytotoxicity. Cytotoxic activity of transfused HPV CD8+ T cells (E7-specific) was proven to be potentially effective against cervical cancer. In other words, it can be said that the expansion and potentiation of CTL activity (tumour-specific) is augmented by a combination of IL-10 and IL-2 for clinical use in the therapy of cancer (Santin et al., 2000). Also, cytotoxic CD8+ T cells (HPV-specific) when generated in vitro by E7 pulsed autologous DC, were efficient in destroying naturally autologous tumourcells (HPV-infected) when applied in patients suffering from invasive cervical cancer. Dominance in expression of intracellular type I cytokine by the human leukocytic antigen (HLA) class I- restricted CTLs has been noted i.e. there is higher levels of expression of IFN-γ; IL-2; and TNF-α and low level of expression of IL-4 (Pittet et al., 2000; Santin et al., 2000; McHugh et al., 2001).

8.2 Gastrointestinal (GI) cancer

The advanced stage of GI cancer is a virulent disease with a poor prognosis inspite of multidisciplinary treatment. For clarification of the effects of CTLs (tumorspecific) therapy clinically as a multidisciplinary treatment for patients having cancer at advanced state studies has been conducted. It is crucial to note that there is distant metastasis in case of patients having advanced stage of GI cancer and is derived from gastric cancer; colon cancer; as well as bilio-pancreatic cancer. After providing adoptive immunotherapy based on CTLs it has been observed that such patients develop no severe toxicity. However, there is development of fever as well as myelosuppression. Clarification has been done and it has been found that as multidisciplinary treatment CTL therapy is valuable clinically particularly in terms of standards of life. As a mode of development of new cancer prevention strategy cancer vaccine which is carcino embryogenic antigen (CEA) specific have just been started (Tsunoda et al., 1999; El-Omar et al., 2003; Zhang & An, 2007).

10 Chemotherapy and CTL-mediated killing

A serious challenge is faced by immunotherapy against cancer due to low efficacy clinically. As per recent clinical study reports the clinical response rate is higher in case of several types of cancer when cancer vaccine and chemotherapy are used. Various anti cancer vaccines and chemotherapeutic drugs have been tested in mice along with approaches to transfer adoptive T cells. The tumourcells become more susceptible to the effect of cytokotoxic CTL due to chemotherapy (Zou, 2006; Dhama et al., 2013a). This is achieved in the body by making tumourcells increasingly permeable to granzyme B (perforin-independent) using drugs viz., paclitaxel (TAX); cisplatin (CIS); and doxorubicin (DOX) etc. which can then sensitize tumourcell to CTLs. These drugs act via up regulation of mannose-6-phosphate receptor expression on the surface of tumourcell. Apoptosis can be introduced in neighbouring tumourcells by using chemotherapy and CTLs (raised against specific antigen) combinedly without those antigens getting expressed. It is therefore suggestive of the fact that CTLs in small numbers can mediate anti-tumoreffect potentially together with chemotherapy (Veugelers et al., 2006; Zou, 2006; Zitvogel et al., 2008; Ramakrishnan et al., 2008; Ramakrishnan et al., 2010). Docetaxel (a taxane) has been found to increase the susceptibility of tumours of human origin to CTL mediated killing (Hodge et al., 2013). Studies have shown that the CTL percentage increases in patients with breast cancer when treated by following epirubicin regimen (5-fluouracil; epirubicin; and cyclophosphamide) (Bracci et al., 2014).

Conclusion and future perspectives

The researchers have described cytotoxic T cells as serial killer due to their antigen-specific cytolytic action towards cancer through CTL clones with unique TCR and they certainly play definitive role to keep good health. Features such as the ability to mount defence against malignancies of diverse origin due to the ubiquitous expression of MHC class I molecules, immunity against systemic diseases through the continuous recirculation throughout the body, highly sensitive target recognition even with very little peptide-MHC complex, indirect anti-tumor action especially by non-lytic effector mechanisms through interferon...
gamma etc. render them as promising candidates of anti-tumorimmunity. In our body, the CTLs are billions in numbers recognizing the cancerous cells through markers on the cell surface. It has been demonstrated by scientists that in the cell packaging parts of the body the lethal hit must be focused by the CTLs on the target exception to which may lead to collateral damage to the cells of the neighboring regions that are healthy. There is sealing of the fate of the cancer cell once there is injection of cytotoxins into the cancer cells resulting in its death. Researches have been conducted much vividly to explore the role of CTLs in cancer immunotherapy and for development of T cell based vaccines. Various trials based on cellular immunotherapy have come up with clinically proven potential of CTLs in adoptive immunotherapy against cancer cells. But advances are still warranted in this field for the expansion of CTL based therapy in terms of quickly targeting tumorantigens (relevant) ex vivo, potency in preventing the recurrence of tumor once treated, and cost-effectiveness of the therapy thereby making it more potential and popular in countering different cancerous conditions.

Funding

This compilation is a review article written, analyzed and designed by its authors and required no substantial funding to be stated.

Acknowledgement

All the authors acknowledge and thank their respective Institutes and Universities.

Conflicts of interest

All authors declare that there exist no commercial or financial relationships that could in any way lead to a potential conflict of interest.

References

Abbas AK, Lichtman AH, Pillai S (2007) Cellular and molecular immunology, 6th ed.; Saunders Elsevier: Philadelphia, PA USA, Pp. 267–301.

Acharya N, Gohel D, Kuberkar V, Natesan S (2015) Recent advances in immunotherapy for the treatment of cancer. Advances in Animal and Veterinary Sciences 3: 23–29.

Aerts JG, Hegmans JP (2013) Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer. Cancer Research 73: 2381–2388.

Aerts JG, Lievense LA, Hoogsteden HC, Hegmans JP (2014) Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Translational Lung Cancer Research 3: 34–45.

Ahmad K, Rabbani G, Baig MH, Lim JH, Khan ME, Lee EJ, Ashraf GM, Choi I (2017) Nanoparticle-based drugs: An armament for effective anti-cancer therapy. Current Drug Metabolism 2017 Aug 22. doi: 10.2174/187220321866617082315647. [Epub ahead of print]

Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nature Reviews Immunology 1: 220–228.

Ambrosino E, Terabe M, Halder RC (2007) Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. The Journal of Immunology 179: 5126–5136.

Andersen MH, Sorensen BS, Brinnes M, Svane IM, Becker JC, ThorStraten P (2009) Identification of heme Oxygenase-1-specific regulatory CD8+ T cells in cancer patients. The Journal of Clinical Investigation 119: 2245–2256.

Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. Journal of Clinical Oncology 30: 2678–2683.

Beatty PR, Krams SM, Martinez OM (1997) Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. The Journal of Immunology 158: 4045–4051.

Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D (2013) Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clinical Cancer Research 19: 4792–4800.

Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death and Differentiation 21: 15–25.

Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lydiane C, King PD, Larson S, Weiss M, Riviere I, Sadelain M (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Medicine 9: 279–286. DOI:10.1038/nm827.

Brigl M, Brenner MB (2004) CD1: antigen presentation and T cell function. Annual Review of Immunology 22: 817–890.

Callan MF, Tan L, Annels N, Ogg GS, Wilson JD, O’Callaghan

http://www.jebas.org
Cytotoxic T cells and Cancer Therapy

CA, Steven N, McMichael AJ, Rickinson AB (1998) Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein–Barr virus in vivo. The Journal of Experimental Medicine 187: 1395–1402.

Cerundolo V, Hermans IF, Salio M (2004) Dendritic cells: a journey from laboratory to clinic. Nature Immunology 5: 7-10. DOI:10.1038/ni0104-7.

Chesson CB, Ekpo-Otu S, Endsley JJ, Rudra JS (2017) Biomaterials-based vaccination strategies for the induction of CD8+ T cell responses. ACS Biomaterials Science and Engineering 3: 126-143.

Clay TM, Hobeka AC, Mosca PJ, Lyerly HK, Morse MA (2001) Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clinical Cancer Research 7: 1127–1135.

Coulie PG, van der Bruggen P (2003) T-cell responses of vaccinated cancer patients. Current Opinion in Immunology 15: 131–137. DOI: 10.1016/S0952-7915(03)00009-8.

Curiel TJ (2007) Tregs and rethinking cancer immunotherapy. The Journal of Clinical Investigation 117: 1167–1174.

Dadar M, Dhama K, Iqbal HMN, Munjal A, Khandia R, Karthik K, Sachan S, Latheef SK, Samad HA, Joshi SK (2016) Molecular signatures of biomarkers in cancer development, diagnosis, and its prognostic accuracy. Current Biomarkers 6 : 89-96. DOI: 10.2174/24684228076661702101642 5

D’Errico G, Machado HL, Sainz B (2017) A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. Clinical and Translational Medicine 6:3. doi: 10.1186/s40169-016-0130-5.

Dhama K, Chakraborty S, Wani MY, Tiwari R, Barathidasan R (2013a) Cytokine therapy for combating animal and human diseases. Research Opinions in Animal and Veterinary Sciences 3: 195-208.

Dhama K, Mani S, Chakraborty S, Tiwari R, Kumar A, Selvaraj P, Rai RB (2013b) Herbal remedies to combat cancers in humans and animals – a review. International Journal of Current Research 5: 1908-1919.

Dhama K, Chakraborty S, Tiwari R (2013c) Panchgavya therapy (Cowpatri) in safeguarding health of animals and humans – A review. Research Opinions in Animal and Veterinary Sciences 3: 170-178.

Dhama K, Chakraborty S, Tiwari R, Verma AK, Saminathan M, Amarpal, Malik YS, Nikousefat Z, Javdani M, Khan RU (2014) A concept paper on novel technologies boosting production and safeguarding health of humans and animals. Research Opinions in Animal and Veterinary Sciences 4: 353-370.

Dhama K, Mani S, Jacob SS, Singh M, Karthik K, Amarpal, Tiwari R, Sunkara LT, Malik YS, Singh RK (2015) Effect of immunomodulation and immunomodulatory agents on health with some bioactive principles, modes of action and potent biomedical applications. International Journal of Pharmacology 11: 253-290.

Dhama K, Sachan S, Khandia R, Munjal A, Iqbal HMN, Latheef SK, Karthik K, Samad HA, Tiwari R, Dadar M (2016) Medicinal and beneficial health applications of Tinospora cordifolia (Guduchi): A miraculous herb countering various diseases/disorders and its Immunomodulatory effects. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 10: 96-110. DOI: 10.2174/1872241811666170301105101

Dharnidharka VR, Araya CE (2009) Post-transplant lymphoproliferative disease. Pediatric Nephrology 24 : 731-736.

Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S (2016) Post-transplant lymphoproliferative disorders. Nature Reviews Disease Primers 2: 15088.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Frezeer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850–854.

Eberl G, Brawand P, MacDonald HR (2000) Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation. The Journal of Immunology 165: 4305–4311.

Ekkens MJ, Shedlock DJ, Jung E, Troy A, Pearce EL, Shen H, Pearce EJ (2007) Th1 and Th2 Cells Help CD8 T-Cell Responses. Infection and Immunity 75 : 2291–2296.

El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ (2003) Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124: 1193–1201.

Faroudi M, Utzny C, Salio M, Cerundolo V, Guiraud M, Muller S, Valitutti S (2003) Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: Manifestation of a dual activation threshold. Proceedings of National Academy of Sciences, USA. 100:14145–14150.
Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nature Reviews Immunology 3: 630–641. DOI: 10.1038/nri1150.

Finney HM, Akbar AN, Lawson AD (2004) Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. The Journal of Immunology 172: 104–113.

Freiberg BA, Kuper H, Maslanik W, Delli J, Kappler J, Zaller DM, Kuper A (2002) Staging and resetting T-cell activation in SMACs. Nature Immunology 3: 911–917.

Friedl P, den Boer AT, Gunzer M (2005) Tuning immune responses: diversity and adaptation of the immunological synapse. Nature Reviews Immunology 5:532–545.

Freigang S, Probst HC, van den Broek M (2005) DC infection promotes antiviral CTL priming: the ‘Winkelried’ strategy’. Trends in Immunology 26: 13–18.

Fujii SI, Liu K, Smith C, Bonito AJ, Steinman RM (2004) The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. The Journal of Experimental Medicine 199: 1607–1618.

Fujii SI, Shimizu K, Smith C, Bonifaz L, Steinman RM (2003) Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a co-administered protein. The Journal of Experimental Medicine 198: 267–279.

Fujii S, Shimizu K, Hemmi H, Fukui M, Bonito AJ, Chen G, Franck RW, Tsuji M, Steinman RM (2006) Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proceedings of National Academy of Sciences, U.S.A. 103: 11252–11257.

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 9: 162–174.

Gilboa E (1999) How tumors escape immune destruction and what we can do about it. Cancer Immunology, Immunotherapy 48: 382–385.

Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nature Medicine 7: 1118–1122. doi:10.1038/nm1001-1118.

Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K (2002) Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. The Journal of Immunology 169: 575–580.

Groscurth P, Filgueira L (1998) Killing mechanisms of cytotoxic T lymphocytes. Physiological Reports 13: 17-21.

Grosso JF, Jure-Kunkel MN (2013) CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunity13:5.

Hanlon AM, Jang S, Salgame P (2002) Signaling from cytokine receptors that affect Th1 responses. Frontiers in Bioscience 7: d1247–d1254.

Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K (2001) Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. The Journal of Immunology 166: 6012–6018.

Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100: 3155–3163. DOI: 10.1182/blood-2002-04-1041.

Hermans IF, Silk JD, Gileadi U (2003) NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. The Journal of Immunology 171: 5140–5147.

Hivroz C, Chemin K, Tourret M, Bohineust A (2012) Crosstalk between T Lymphocytes and Dendritic Cells. Critical Reviews in Immunology 32: S. 139. DOI: 10.1615/CritRevImmunol.v32.i2.30.

Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR (2013) Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. International Journal of Cancer 133: 624–636.

Hoyer S, Prommersberger S, Pfeiffer IA, Schulter-Thurner B, Schuler G, Dörrie J, Schaft N (2014) Concurrent interaction of DCs with CD4 and CD8 T cells improves secondary CTL expansion: It takes three to tango. European Journal of Immunology 44: S. 3543. DOI: 10.1002/eji.201444477.
Ikeda H, Chamoto K, Tsuji T (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Science 95: 697–703.

Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM (1995) Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. European Journal of Immunology 25:1071–1079.

Ito H, Seishima M (2010) Regulation of the induction and function of Cytotoxic T lymphocytes by Natural Killer T cell. Journal of Biomedicine and Biotechnology, Article ID: 641757, 8 pages. http://dx.doi.org/10.1155/2010/641757.

Iqbal HMN, Villalba A, Khandia R, Munjal A, Dhama K (2016) Recent trends in nanotechnology-based drugs and formulations designed for targeted therapeutic delivery. Recent Patents on Inflammation & Allergy Drug Discovery 10: 86-93.

Jahng A, Marcic I, Aguiler C, Cardell S, Halder RC, Kumar V (2004) Prevention of autoimmunity by targeting a distinct, non-invariant CD1d-reactive T cell population reactive to sulfatide. The Journal of Experimental Medicine 199: 947–957.

Jaquer E, Jaquer D, Knuth A (1999) CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer and Metastasis Reviews 18: 143-150.

Johnson TR, Hong S, Van Kaer L, Koezuka Y, Graham BS (2002) NK T cells contribute to expansion of CD8+ T cells and amplification of antiviral immune responses to respiratory syncytial virus. Journal of Virology 76: 4294–4303.

Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Enk AH (2001) Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. The Journal of Experimental Medicine 193: 1285–1294.

June CH (2007) Adoptive T cell therapy for cancer in the clinic. The Journal of Clinical Investigation 117: 1466-1476.

Kenter GG, Weelte MJ, Valentijn AR, Lowik MJ, Berends-van Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Van der Burg SH, Melief CJ (2008) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clinical Cancer Research 14: 169–177.

Kenter GG, Weelters MJ, Valentijn AR, Lowik MJ, Berends-van Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Van der Burg SH, Melief CJ (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. The New England Journal of Medicine 361: 1838–1847.

Kershaw MH, Westwood JA, Slaney CY, Darcy PK (2014) Clinical application of genetically modified T cells in cancer therapy. Clinical and Translational Immunology 3:e16.

Khandia R, Sachan S, Munjal AK, Tiwari R, Dhama K (2016a) Tumor Homing Peptides: Promising Futuristic Hope Therapy. In: Atta-ur-Rahman, Khurshid Zaman (Eds.) Patent eBook series entitled Topics in Anti-Cancer Research e-book. Volume 5, Bentham Science Publishers Pp. 43–86.

Khandia R, Munjal AK, Hafiz MN, Iqbal, Kuldeep Dhama (2016b) Heat shock proteins: Therapeutic perspectives in inflammatory disorders. Recent Patents on Inflammation & Allergy Drug Discovery 10: 94-104.

Khandia R, Pattnaik B, Rajukumar K, Pateriya A, Bhatta S, Murugkar H, Prakash A, Pradhan HK, Dhama K, Munjal A, Joshi SK (2017a) Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential. Oncotarget 8: doi: 10.18632/oncotarget.16214

Khandia R, Munjal A, Kumar A, Singh G, Karthik K, Kuldeep Dhama (2017b) Cell penetrating peptides: Biomedical/therapeutic applications with emphasis as promising futuristic hope for treating cancer. International Journal of Pharmacology, 13: 677-689.

Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ (2008) Next generation of immunotherapy for melanoma. Journal of Clinical Oncology 26: 3445–3455.

Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8+ T-cell immunity in cancer patients. The Journal of Clinical Investigation 107: 477–484.

Kumar R, Patel SK, Rami Reddy BV, Bhatt M, Karthik K, Gandham RK, Malik YS, Dhama K (2015) Apoptosis and other alternate mechanisms of cell death. Asian Journal of Animal and Veterinary Advances 10: 646-668.

Kurzrock R (2000) Cancer Medicine, 5th ed.; BC Decker: Hamilton, Canada, pp. 66-178.
Lanzavecchia A (1998) Licence to kill. Nature 393: 413–414.

Latouche JB, Sadelain M (2000) Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nature Biotechnology 18: 405–409. DOI:10.1038/74455.

Le DT, Pardoll DM, Jaffee EM (2010) Cellular vaccine approaches. The Cancer Journal 16: 304–310.

Lippitz BE (2013) Cytokine patterns in patients with cancer: a systematic review. Lancet Oncology, 14: e218–e228.

Ludewig B, Odermatt B, Ochsenbein AF, Zinkernagel RM, Hengartner H (1999) Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunological Reviews 169: 45–54.

Lui-Roberts WW, Stinchcombe JC, Ritter AT, Akhmanova A, Karkesisoglu I, Griffiths GM (2012) Cytotoxic T lymphocyte effector function is independent of nucleus-centrosome dissociation. European Journal of Immunology 42: 2132-2141.

Lutzky VP, Crooks P, Morrison L, Stevens N, Davis JE, Corban M, Hall D, Panizza B, Coman WB, Coman S, Moss DJ (2014) Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clinical and Vaccine Immunology 21: 256-259.

Mackensen A, Meidenbauer N, Vogl S, Launer M, Berger J, Andresen R (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. Journal of Clinical Oncology 24: 5060-5009.

Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M (2002) Human T lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR/CD28 receptor. Nature Biotechnology 20: 70–75. DOI:10.1038/nbt0102-70.

Maher J (2012) Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncology 2012: 278093. doi: 10.5402/2012/278093.

Maher J, Davies ET (2004) Targeting cytotoxic T lymphocytes for cancer immunotherapy. British Journal of Cancer 91: 817-821.

Makkouk A, Weiner GJ (2015) Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Research 75: 5-10. doi: 10.1158/0008-5472.

Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Advances in Immunology 74: 181–273.

Matsui S, Ahlers JD, Vortmeyer AO (1999) A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. The Journal of Immunology 163: 184–193.

Matteo I, Giovanni S, Masanori I, Patrizia M, Maria GC, Pedro RL, Francis VC, Zaverio MR, Luca GG (2005) Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nature Medicine 11: 1167–1169.

Matteo I, Giovanni S, Luca GG (2006) Pathogenetic and antiviral immune responses against hepatitis B virus. Future Virology 1: 189–96. DOI:10.2217/17460794.1.2.189.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez YE, Zheng Z, Lacey SF, Mahnke YD (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine 371: 1507-1517.

McHugh RS, Shevach EM, Thornton AM (2001) Control of organ-specific autoimmunity by immunoregulatoryCD4(+)CD25(+) T cells. Microbes and Infection 3: 919–927.

McNally A, Hill GR, Sparwasser T, Thomas R, Steptoe RJ (2011) CD44+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis. Proceedings of the National Academy of Sciences, USA 108: 7529–7534.

Metelista LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kronenberg M, Seeger RC (2001) Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells. The Journal of Immunology 167: 3114-3122.

Milstein O, Hagi D, Lask A, Reich-Zeliger S, Shezan E, Ophir E, Eidelstein Y, Afik R, Antebi YE, Dustin ML, Reisner Y (2011) CTLs respond with activation and granule secretion when serving target for T cell recognition. Blood 117: 1042-1052.

Mohanty I, Arunvikram K, Behera D, Milton AAP, Elaiyaraja G, Rajesh G, Dhamu K (2016). Immunomodulatory and therapeutic potential of zootoxins (venom and toxins) on the way towards designing and developing novel drugs/medicines : An overview. International Journal of Pharmacology 12: 126-135.

Morris EC, Bendle GM, Stauss HJ (2003) Prospects for immunotherapy of malignant disease. Clinical & Experimental Immunology 131: 1–7. DOI: 10.1046/j.1365-2249.2003.02055.x.

Morris EC, Stauss HJ (2016) Optimizing T-cell receptor gene therapy for hematologic malignancies. Blood 127(26): 3305–3311.
Nakanishi Y, Lu B, Gerard C, Iwasaki A (2009) CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature 462:510–513.

Nelson BH (2004) IL-2, regulatory T cells, and tolerance. The Journal of Immunology 172: 3983–3988.

Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R (2006) Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Research 66: 6387-6394.

Padua RA, Larghero J, Robin M, Le Pogam C, Schlageter MH, Muszlak S, Fric J, West R, Rousselot P, Phan TH, Mudd L, Teisserenc H, Carpenter AF, Kogan S, Degos L, Pla M, Bishop JM, Stevenson F, Charron D, Chomienne C (2003) PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nature Medicine 9: 1413–1417. DOI: 10.1038/nm949.

Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, Pacienza-Gros M, Poizat F, Bendjebbi M, Azario-Cheillan F, Walz J, Salem N, Brunelle S, Moretta A, Olive D (2016) Inherent and tumour-driven immune tolerance in the prostate microenvironment impairs natural killer cell anti-tumouractivity. Cancer Research 76:1-13.

Perica K, Varela JC, Oelke M, Schneck J (2015) Adoptive T cell immunotherapy for cancer. Rambam Maimonides Medical Journal 6: e0004.

Phares TW, Stohlman SA, Hwang M, Min B, Hinton DR, Bergmann CC (2012) CD4 T cells promote CD8 T cell immunity at the priming and effector site during viral encephalitis. Journal of Virology 86 : 2416-2427.

Pittet MJ, Speiser DE, Valmori D, Cerottini J-C, Romero P (2000) Cytolytic effector function in human circulating CD8+ T cells closely correlated with CD56 surface expression. The Journal of Immunology 164: 1148–1152.

Prlic M, Blazar BR, Farrar MA, Jameson SC (2003) In vivo survival and homeostatic proliferation of natural killer cells. The Journal of Experimental Medicine 197: 967–976.

Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Research 63: 4095–4100.

Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakraborty S, Dhama K (2014) Oxidative stress, prooxidants and antioxidants: the interplay. BioMed Research International Volume 2014, Article ID 761264, 19 pages. http://dx.doi.org/10.1155/2014/761264.

Rajasagi NK, Kassim SH, Kollias CM, Zhao X, Chervenak R, Jennings SR (2009 ) CD4+ T cells are required for the priming of CD8+ T cells following infection with herpes simplex virus type 1. Journal of Virology 83:5256–5268.

Ramakrishnan R, Antonia S, Gabrilovich DI (2008) Combined modality immunotherapy and chemotherapy: a new perspective. Cancer Immunology and Immunotherapy 57:1523–1529.

Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho H, Antonia S, Altior C, Celis E, Gabrilovich I (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. The Journal of Clinical Investigation 120: 1111-1124.

Roooney CM, Smith CA, Ng CYC, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Kranze RA, Brenner MK, Heslop HE (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.

Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of patients with metastatic melanoma with autologous tumor lymphocytes and interleukin 2. Journal of the National Cancer Institute 86 : 1159–1166.

Rosenberg SA, Yang JC, Sherry RM, Kammla US, Hughes MS, Phan GQ, Citrin D, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research 17: 4550–4557.

Rossig C, Bolland CM, Nuchtern G, Rooney CM, Brenner MK (2002) Epstein–Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood 99: 2009–2016.

Sakaguchi S (2000) Regulatory t cells: Key controllers of immunologic self-tolerance. Cell 101: 455.

Saminathan M, Rai RB, Dhama K, Tiwari R, Chakraborty S, Amarpal, Ranganath GJ, Kannan K (2013) Systematic review on...
anticancer potential and other health beneficial pharmacological activities of novel medicinal plant *Morinda citrifolia* (Noni). International Journal of Pharmacology 9: 462-492.

Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Roman JJ, Parham GP, Cannon MJ (2000) Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papilloma virus-Specific CD8+ Cytotoxic T Lymphocytes. Journal of Virology 74: 4729-4737.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) Ifn-gamma and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature 410: 1107–1111.

Shanker A, Thounaojam MC, Mishra MK, Dikov MM (2017) Innate-adaptive immune crosstalk 2016. Journal of Immunology Research Volume 2017. Article ID 3503207, 2 pages.

Sharpe M, Mount N (2015) Genetically modified T cells in cancer therapy: opportunities and challenges. Disease Models and Mechanisms 8: 337-350.

Sherritt MA, Bharadwaaj M, Burrows JM, Morrison LE, Elliott SL, Davis JE, Kear LM, Slaughter RE, Beel SC, Galbraith, AJ, Khanna R, Moss DJ (2003) Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from post-transplant lymphoma after adoptive immunotherapy. Transplantation 75:1556-1560.

Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT (2004) Cognate CD4+ T cell licensing of dendritic cells in CD8+ cell immunity. Nature Immunology 5:1143–1148.

Stinchcombe JC, Griffiths GM (2001) Normal and abnormal secretion by haemopoietic cells. Immunology 103: 10–16.

Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morris MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney, CM, Heslop HE (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105: 1898–1904.

Subramanian S, Ramalingam K (2005) Electron microscopic evidence on the participation Cytotoxic T Lymphocytes and Macrophages in Mtb adjuvant induced connective tissue inflammation and arthritogenesis in Rattus norvegicus. Asian Journal of Microbiology, Biotechnology and Environmental Sciences 7: 227–233.

Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN (1996) Evidence that a single peptide–MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4: 565–571.

Takahashi T, Nieda M, Koenzuka Y, Nicol A, Porcelli SA, Ishikawa Y, Tadokoro K, Hirai H, Juji T (2000) Analysis of human Vα24+CD4+ NKT cells activated by α-glycosylceramide-pulsed monocyte-derived dendritic cells. The Journal of Immunology 164: 4458-4464.

Taniguchi M, Seino KI, Nakayama T (2003) The NKT cell system: bridging innate and acquired immunity. Nature Immunology 4: 1164–1165.

Taniguchi M, Harada M, Dashtsoodol N, Kojo S (2015) Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy. Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences 91: 292–304.

Terabe M, Matsui S, Noben-Trauth N (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunology 1: 515–520.

Terabe M, Swann J, Ambrosino E (2005) A non-classical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. The Journal of Experimental Medicine 202: 1627–1633.

Tsunoda T, Tanimura H, Yamae H, Tanaka H, Matsuda K (1999) Tumor specific CTL therapy for advanced cancer and development for cancer vaccine. Hepatogastroenterology 46: 1287-1292.

Uldrich AP, Crowe NY, Kyparissoudis K (2005) NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. The Journal of Immunology 175: 3092–3101.

Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunological Reviews 188: 51–64.

Veugelers K, Motyka B, Goping IS, Shostak I, Sawchuk T, Bleackley RC (2006) Granule-mediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparansulfate. Molecular Biology of the Cell 17: 623–633.

Vinay DS, Choi BK, Bae JS, Kim WY, Gebhardt BM, Kwon BS (2004) CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced
shock syndromes, and have lower IL-4 responses. The Journal of Immunology 173: 4218–4229.

Whelan M, Whelan J, Russell N, Dalgleish A (2003) Cancer immunotherapy: an embarrassment of riches. Drug Discovery Today 8: 253–258. DOI: 10.1016/S1359-6446(03)02633-3.

Wiedemann A, Depoil D, Faroudi M, Valitutti S (2006) Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. Proceedings of National Academy of Sciences USA 103: 10985-10990.

Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W (2011) Th17 cells in cancer: Help or hindrance? Carcinogenesis 32: 643–649.

Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proceedings of National Academy of Sciences, USA 99: 16168–16173.

Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD (2000) Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. The Journal of Experimental Medicine 192: 1637-1644.

Ye B, Stary CM, Gao Q, Wang Q, Zeng Z, Jian Z, Gu L, Xiong X (2017) Genetically modified T-cell-based adoptive immunotherapy in hematological malignancies. Journal of Immunology Research 2017: 5210459.

Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu Y-X (2004) Priming of naïve T cells inside tumors leads to eradication of established tumors. Nature Immunology 5: 141–149. DOI: 10.1038/ni1029.

Zhang JM, An J (2007) Cytokines, Inflammation and Pain. International Anesthesiology Clinics 45: 27–37.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immune surveillance against cancer. Nature Reviews Immunology 8: 59–73.

Zou W (2006) Regulatory T cells, tumor immunity and immunotherapy. Nature Reviews Immunology 6: 295–307.

Zou W, Restifo NP (2010) T (h)17 cells in tumor immunity and immunotherapy. Nature Reviews Immunology10: 248–256.